Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right ventricular systolic function strain and myocardial fibrosis assessment.
The objective of this study is to compare the accuracy of 3D TTE to 2D TTE in assessing the severity of valvular heart disease in patients with aortic stenosis, aortic regurgitation, and mitral valve regurgitation by comparing this to the reference standard of cardiac magnetic resonance (CMR) in subjects with different etiologies and mechanisms of valvular lesions and to the integrative method of valvular lesion grading as recommended by inter-societal guidelines. Another objective is to assess prevalence of focal and diffuse myocardial fibrosis as assessed by CMR in patients with aortic stenosis, aortic regurgitation and mitral regurgitation. In addition, the investigators aim to determine whether severity of myocardial fibrosis predicts onset of symptoms, referral for valve surgery and adverse ventricular remodeling. The investigators also aim to look at patients who will be undergoing CRT implant to predict their response to therapy.
At baseline, the Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire will be completed. A 6-12 month follow-up is required and will include an abbreviated non-contrast research cardiac MRI and subject questionnaires.
Other follow-up will include using electronic medical records and the Social Security Death Index database for outcomes such as death, hospitalization for heart failure, mitral or aortic valve interventions and cardiovascular death.
Select patients will be asked to undergo a supine bicycle exercise stress MRI at enrollment. Approximately 40 subjects will be included in this substudy.
Additional exclusion criteria for this substudy:
During the exercise stress MRI, patients will be asked to cycle on a supine bike that will be mounted on the MRI platform. During this test, a caregiver will be present. An electrocardiogram (ECG) will be used to obtain tracings of cardiac activity. Respirations, blood pressure, and heart rate are also monitored during exercise. The test is continued until peak exercise level or target heart rate is achieved. As soon as the exercise portion is complete, MRI images will be acquired. When the test is complete, patients will be monitored until ECG, heart rate, and breathing have returned to baseline. Patients will be assessed for symptoms such as chest pain, dyspnea, leg pain, dizziness, or fatigue and may be given medications or instructed to stop the test early as necessary.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mitral Valve Regurgitation | Patients with moderate or severe (3+ or 4+) mitral valve regurgitation on the basis of prior known clinical history or clinical exam. |
| |
| Aortic Valve Regurgitation | Patients with moderate or severe (3+ or 4+) aortic valve regurgitation on the basis of prior known clinical history or clinical exam. |
| |
| Aortic Stenosis | Patients with moderate or severe (3+ or 4+) aortic stenosis on the basis of prior known clinical history or clinical exam. |
| |
| Patients referred for CRT Implantation | Patients who meet clinical guideline criteria for CRT implantation with EF < 40% |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MRI with strain measurement | Diagnostic Test | CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in MRI Quantified LVEDVi | 10% Change from Baseline - units of measure cc/m2 | 6 months |
| Change in MRI Quantified LVESVi | 15% Change from Baseline - units of measure cc/m2 | 6 months |
| Change in MRI Quantified LV Strain | 5% Change from Baseline | 6 months |
| Change in MRI LVEF | 5% Change from Baseline | 6 Months |
| Change in Kansas City Cardiomyopathy Questionnaire Answers | Change in quality of life related to heart failure symptoms. | 6 Months |
| Change in Physical Activity Questionnaire Answers | Change in physical activity level due to heart failure symptoms. | 6 Months |
| All-cause mortality | number of patients expired | 6 Months |
| Development of class I or IIa indication for valve surgery | The recommended indications for surgery include: development of symptoms, LV dysfunction (LV end-systolic diameter ≥45 mm or LV ejection fraction ≤60%), and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary artery pressure >50 mm Hg at rest). |
| Measure | Description | Time Frame |
|---|---|---|
| Accuracy of echocardiography as compared with MRI | Comparison of MRI measurements based on standard of care echocardiography. | 6 Months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with suspected chronic AS, AR, MR or heart failure with reduced ejection fraction being evaluated for CRT implantation referred for clinically indicated CMR and echocardiography by their cardiologists.. CMR and echocardiography will be clinically indicated in this study group.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Deborah Kwon, M. D. | Contact | 216-444-8526 | kwond@ccf.org |
| Name | Affiliation | Role |
|---|---|---|
| Deborah Kwon, M. D. | The Cleveland Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cleveland Clinic | Recruiting | Cleveland | Ohio | 44195 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006349 | Heart Valve Diseases |
| D001024 | Aortic Valve Stenosis |
| D001022 | Aortic Valve Insufficiency |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D000082862 | Aortic Valve Disease |
| D014694 | Ventricular Outflow Obstruction |
Not provided
Not provided
| ID | Term |
|---|---|
| D008279 | Magnetic Resonance Imaging |
| D004452 | Echocardiography |
| ID | Term |
|---|---|
| D014054 | Tomography |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
As part of an optional sub study, subjects will be asked to provide blood samples at the baseline visit. Up to 5 tablespoons (75ml) of blood will be drawn. Genomic analyses will be run on the samples to look for biomarkers which may correlate with the development of myocardial fibrosis.
| Echocardiography | Diagnostic Test | Doppler, PISA, VCA, volumetric method as performed during echocardiography |
|
| 6 Months |
| D057791 |
| Cardiac Imaging Techniques |
| D014463 | Ultrasonography |
| D006334 | Heart Function Tests |
| D003935 | Diagnostic Techniques, Cardiovascular |